Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to MarketBeat Daily Ratings so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
NASDAQ:GRI

GRI Bio (GRI) Stock Price, News & Analysis

→ Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad)
Free GRI Stock Alerts
0.42
+0.01 (+1.82%)
(As of 05/17/2024 08:53 PM ET)
Compare
Today's Range
0.41
▼
0.45
50-Day Range
0.39
▼
0.85
52-Week Range
0.38
▼
49.28
Volume
254,500 shs
Average Volume
520,891 shs
Market Capitalization
$1.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media
GRI stock logo

About GRI Bio Stock (NASDAQ:GRI)

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

GRI Stock Price History

GRI Stock News Headlines

May 16, 2024 | americanbankingnews.com
GRI Bio (NASDAQ:GRI) Shares Down 1.2%
May 15, 2024 | washingtonpost.com
Ziopharm: Q1 Earnings Snapshot
May 14, 2024 | finance.yahoo.com
GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase
May 14, 2024 | globenewswire.com
GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase
May 13, 2024 | msn.com
GRI Stock Earnings: GRI Bio Reported Results for Q1 2024
May 13, 2024 | globenewswire.com
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 13, 2024 | americanbankingnews.com
GRI Bio (NASDAQ:GRI) Releases Earnings Results
May 2, 2024 | msn.com
Babraham-based Harness Therapeutics appoints Meenu Chhabra Karson as board chair
April 29, 2024 | globenewswire.com
GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity
April 25, 2024 | globenewswire.com
GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
April 18, 2024 | finanznachrichten.de
GRI Bio, Inc.: GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent
April 16, 2024 | globenewswire.com
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent
April 8, 2024 | globenewswire.com
GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference
April 1, 2024 | globenewswire.com
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
March 28, 2024 | globenewswire.com
GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference
March 14, 2024 | finanznachrichten.de
GRI Bio, Inc.: GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators
March 14, 2024 | finance.yahoo.com
GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators
March 14, 2024 | globenewswire.com
GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators
March 4, 2024 | finanznachrichten.de
GRI Bio, Inc.: GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom
March 4, 2024 | globenewswire.com
GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom
February 23, 2024 | benzinga.com
Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)
February 3, 2024 | msn.com
GRI Bio Launches Major Securities Public Offering
February 2, 2024 | msn.com
GRI Bio prices 5M shares at $1.10 in public offering
February 2, 2024 | marketwatch.com
GRI Bio Shares Drop After Stock Offering Prices Below Thursday's Close
February 2, 2024 | markets.businessinsider.com
GRI Bio Announces Pricing Of $5.5 Mln Public Offering, Stock Down
See More Headlines

Company Calendar

Last Earnings
5/10/2024
Today
5/20/2024
Next Earnings (Estimated)
8/12/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GRI
CUSIP
N/A
CIK
1824293
Web
www.vallon-pharma.com
Phone
267-607-8255
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-13,040,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-548.12%
Return on Assets
-290.50%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.64
Quick Ratio
2.64

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
0.40 per share
Price / Book
1.05

Miscellaneous

Outstanding Shares
3,770,000
Free Float
3,662,000
Market Cap
$1.58 million
Optionable
Not Optionable
Beta
-1.55

Key Executives

  • Dr. W. Marc Hertz Ph.D. (Age 53)
    Co-Founder, CEO, President & Director
    Comp: $842.01k
  • Ms. Leanne M. Kelly (Age 47)
    CFO & Corporate Secretary
    Comp: $550.93k
  • Dr. Vipin Kumar Chaturvedi Ph.D. (Age 64)
    Co-Founder & Chief Scientific Officer
  • Dr. Albert Agro Ph.d. (Age 59)
    Chief Medical Officer

Key Competitors

View All Competitors

GRI Stock Analysis - Frequently Asked Questions

How have GRI shares performed in 2024?

GRI Bio's stock was trading at 2.70 at the beginning of the year. Since then, GRI shares have decreased by 84.4% and is now trading at 0.42.
View the best growth stocks for 2024 here.

When is GRI Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our GRI earnings forecast.

How were GRI Bio's earnings last quarter?

GRI Bio, Inc. (NASDAQ:GRI) announced its earnings results on Friday, May, 10th. The company reported ($0.46) EPS for the quarter.

What ETF holds GRI Bio's stock?

Dimensional International Small Cap Value ETF holds 2,071,221 shares of GRI stock, representing 0.37% of its portfolio.

When did GRI Bio's stock split?

Shares of GRI Bio reverse split on the morning of Tuesday, January 30th 2024. The 1-7 reverse split was announced on Tuesday, January 30th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

How do I buy shares of GRI Bio?

Shares of GRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GRI) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Urgent Nvidia Warning
Altimetry
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
Shocking: One AI startup's revenue could surge 4,735%
Manward Press
"The Biggest Drug Ever" Is Coming
Behind the Markets
Exposed: 10 CENT Crypto to Explode May 20th?
True Market Insiders
CEO of Biggest AI Chipmaker Just Dropped a Bombshell…
Banyan Hill Publishing
Elon’s New Device is About to Shock the World
InvestorPlace
Most important medical advance in 100 years
The Oxford Club